These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11694908)

  • 1. Socioeconomic impact of irritable bowel syndrome in Canada.
    Boivin M
    Can J Gastroenterol; 2001 Oct; 15 Suppl B():8B-11B. PubMed ID: 11694908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic burden of irritable bowel syndrome in Canada.
    Bentkover JD; Field C; Greene EM; Plourde V; Casciano JP
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():89A-96A. PubMed ID: 10202215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical economics review: irritable bowel syndrome.
    Wells NE; Hahn BA; Whorwell PJ
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1019-30. PubMed ID: 9663824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care utilization and economic issues in irritable bowel syndrome.
    Gralnek IM
    Eur J Surg Suppl; 1998; (583):73-6. PubMed ID: 10027677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irritable bowel syndrome in Germany. A cost of illness study.
    Müller-Lissner SA; Pirk O
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1325-9. PubMed ID: 12468953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures.
    Camilleri M; Williams DE
    Pharmacoeconomics; 2000 Apr; 17(4):331-8. PubMed ID: 10947488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irritable bowel syndrome: toward a cost-effective management approach.
    Martin R; Barron JJ; Zacker C
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S268-75. PubMed ID: 11474912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.
    Akehurst RL; Brazier JE; Mathers N; O'Keefe C; Kaltenthaler E; Morgan A; Platts M; Walters SJ
    Pharmacoeconomics; 2002; 20(7):455-62. PubMed ID: 12093301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.
    Hahn BA; Yan S; Strassels S
    Digestion; 1999; 60(1):77-81. PubMed ID: 9892803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of illness of irritable bowel syndrome: current challenges and hope for the future.
    Hulisz D
    J Manag Care Pharm; 2004; 10(4):299-309. PubMed ID: 15298528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: epidemiology and quality of life in functional gastrointestinal disorders.
    Chang L
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():31-9. PubMed ID: 15521853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of irritable bowel syndrome in a managed care setting.
    Patel RP; Petitta A; Fogel R; Peterson E; Zarowitz BJ
    J Clin Gastroenterol; 2002 Jul; 35(1):14-20. PubMed ID: 12080220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological characteristics and socioeconomic importance of irritable bowel syndrome.
    Balboa A; Mearin F
    Rev Esp Enferm Dig; 2000 Dec; 92(12):806-19. PubMed ID: 11468789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms.
    Hahn BA; Saunders WB; Maier WC
    Dig Dis Sci; 1997 Dec; 42(12):2585-90. PubMed ID: 9440642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
    Buono JL; Carson RT; Flores NM
    Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective.
    Longstreth GF; Wilson A; Knight K; Wong J; Chiou CF; Barghout V; Frech F; Ofman JJ
    Am J Gastroenterol; 2003 Mar; 98(3):600-7. PubMed ID: 12650794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.